+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
O

Actively Recruiting

Researchers are evaluating the use of Zanidatamab combined with standard chemotherapy drugs Cisplatin and Gemcitabine, with or without an additional immune therapy drug chosen by the doctor, for adults with HER2-positive biliary tract cancer. This study aims to assess the effectiveness and safety of adding Zanidatamab to the current standard treatment for this advanced cancer type. Participants will be randomly assigned to receive either Zanidatamab plus Cisplatin and Gemcitabine with or without a PD-1L1 inhibitor either Durvalumab or Pembrolizumab or the standard treatment of Cisplatin and Gemcitabine with or without the same immune therapy drugs. All medications are given through intravenous infusions. The study treatment continues under medical supervision and may vary according to local drug approvals. During the trial, participants will have regular assessments including tumor evaluations to measure progression-free survival and overall survival, along with monitoring treatment response and side effects. Patient-reported outcomes on physical functioning and symptom severity will also be collected. The study may last up to several years, with continuous safety monitoring and follow-up visits to evaluate long-term effects and treatment impact.

Age: 18Years +All GendersPhase 3
185 locations
E

Actively Recruiting

Gallbladder cancer GBC is a serious disease often linked to gallstones, especially in women. This research focuses on improving the early detection and prevention of GBC by studying various factors including geography, environment, lifestyle, ethnicity, gender, and molecular markers. The goal is to better estimate the risk of developing GBC and to help guide prevention and treatment decisions, supported by a European-Latin American research collaboration. Participants include those with gallbladder cancer or dysplasia, both before and after starting treatment, as well as individuals with gallstones scheduled for gallbladder removal surgery. The study involves collecting epidemiological, clinical, and dietary data along with biological samples such as blood, saliva, urine, bile, feces, and gallbladder tissue to identify and study new biomarkers and risk factors for GBC. Throughout the study, researchers will use this information to build a biorepository and develop a risk score that integrates multiple factors linked to GBC. They will monitor participants for the development of gallbladder cancer or dysplasia through standard hospital protocols. The study aims to support future personalized prevention strategies and targeted therapies while training new researchers in precision medicine for GBC. Participation involves data and sample collection with ongoing follow-up to assess disease development.

Age: 18Years +All Genders
36 locations
S

Actively Recruiting

Researchers are evaluating a new combination treatment of Sigvotatug Vedotin plus pembrolizumab compared to pembrolizumab alone in people with non-small cell lung cancer NSCLC that has high levels of PD-L1 protein. This protein can limit the bodys immune response to cancer. The study focuses on participants with advanced NSCLC Stage 3 or 4 who have PD-L1 expression in over 50% of their cancer cells and who are eligible for pembrolizumab treatment. All participants will receive pembrolizumab through an intravenous infusion every six weeks at the study clinic. Half of the participants will also receive Sigvotatug Vedotin as an intravenous infusion every two weeks alongside pembrolizumab. Participants may continue pembrolizumab treatment for up to about two years, while those receiving Sigvotatug Vedotin can continue until their cancer no longer responds to treatment. During the study, participants will visit the clinic regularly for monitoring, including assessments of overall survival and progression-free survival over approximately two years. The research team will evaluate how well participants respond to treatment and monitor side effects. Additional laboratory tests will assess drug levels and immune responses. The total study participation may last up to four years, with ongoing evaluations to measure treatment effects and safety.

Age: 18Years +All GendersPhase 3
389 locations